FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA

Provisions in FDA reform legislation that aim to limit the impact of citizen petitions on generic drug approvals are unlikely to provide the relief the generic industry seeks, according to outgoing FDA Chief Counsel Sheldon Bradshaw